Organic Sales Growth
Avient Corporation reported a 0.6% organic sales growth in Q2 2025, and a 1% growth for the first half of the year.
Adjusted EPS Growth
Adjusted EPS grew by 5% to $0.80, slightly ahead of the guidance of $0.79.
Margin Expansion
Adjusted EBITDA margins expanded by 30 basis points to 17.2% in Q2 2025.
Cash Position and Debt Reduction
Strong cash position allowed Avient to pay down $50 million of debt in Q2, with a target to reduce debt by $100 million to $200 million by year-end.
Patent Filings Increase
Patent filings increased by 50% in 2024 compared to 2023, and 2025 is on pace to exceed the previous year's filings.
New Product Innovations
Introduction of new products in healthcare and building materials, including low-temperature chemical forming agents and lubricious characteristics in healthcare materials.